kamau was founded by Matthew Porteus, Valentin Barsan in 2023.

Who are kamau's investors?

kamau's investors include Draper Associates, Khosla Ventures, Modi Ventures, Neva Sgr..

How much funding has kamau raised?

kamau has disclosed $5M raised across 1 round.

Where is kamau headquartered?

kamau is headquartered in Austin, US.

kamau

Austin, US · Founded 2023 · Delaware corporation · 23 employees on LinkedIn · 4 known investors

Find your way into kamau

Your email: who you already know at kamau, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the kamau team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Kamau Therapeutics develops targeted gene integration therapies to treat serious and life-threatening genetic diseases. The company is a clinical-stage biotech firm focused on next-generation gene correction.

Biotech Deep Tech Healthtech

Founders & leadership

kamau was founded in 2023 by Matthew Porteus and Valentin Barsan.

Matthew PorteusCo-founder

Valentin BarsanCo-founder

Board

Raymond KelleherBoard director

Ness BerminghamBoard director

Investors · 4

Draper Associateslisted by Draper AssociatesSan Mateo · $500K – $5M

Khosla Ventureslisted by Khosla VenturesMenlo Park · $5K – $50M

How we know: Khosla Ventures's portfolio page · Not right? Tell us

Modi Ventureslisted by Modi VenturesHouston

How we know: Modi Ventures's portfolio page · Not right? Tell us

Neva Sgr.listed by Neva Sgr.Turin

How we know: Neva Sgr.'s portfolio page · the VCSheet dataset · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$5M disclosed across 1 round · 2025

▶$5MraisedJun 2025 · 6 investors · Other Technology

Rule 506(b)

Officers, directors & promoters on the filing

Raymond KelleherDirector
Matthew PorteusExecutive Officer, Director
Valentin BarsanExecutive Officer, Director
Ness BerminghamDirector

Offering amount: $10M
Amount sold: $5M
First sale: May 2025
Incorporated: Corporation, Delaware, 2023
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 3

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

KenaitxKenai Therapeutics develops iPSC-derived cell therapies and gene-modified medicines for neurodegenerative diseases, particularly Parkinson's disease, leveraging induced pluripotent stem cell technology to replace damaged neurons and restore neural function.

Kano TherapeuticsKano Therapeutics develops circular single-stranded DNA (cssDNA) as a genetic payload for gene-editing and other DNA-based therapies, offering an alternative to viral vectors and double-stranded DNA. It manufactures cssDNA via industrial fermentation and licenses and supplies the payload to therapeutic developers through integrated partnerships spanning discovery to GMP.

Companies working in the same space as kamau.

Frequently asked questions

What does kamau do?: Kamau Therapeutics develops targeted gene integration therapies to treat serious and life-threatening genetic diseases. The company is a clinical-stage biotech firm focused on next-generation gene correction.
Who founded kamau?: kamau was founded by Matthew Porteus, Valentin Barsan in 2023.
Who are kamau's investors?: kamau's investors include Draper Associates, Khosla Ventures, Modi Ventures, Neva Sgr..
How much funding has kamau raised?: kamau has disclosed $5M raised across 1 round.
Where is kamau headquartered?: kamau is headquartered in Austin, US.